Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study

被引:0
|
作者
Han, DF
Zhou, X [1 ]
Hu, MB
Xie, W
Mao, ZF
Chen, DE
Liu, F
Zheng, F
机构
[1] Wuhan Univ, Zhongnan Hosp, Clin Lab Ctr, Wuhan 430071, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Oncol, Wuhan 430071, Peoples R China
[3] Wuhan Univ, Dept Publ Hlth, Wuhan 430071, Peoples R China
关键词
estrogen; metabolizing genes; polymorphism; breast neoplasms; risk factor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Endogenous estrogen plays a very important role in the carcinogenesis and progression of breast cancer. The enzymes involved in the biosynthesis and metabolism of estrogen have been proposed to contribute to this effect. To examine this hypothesis, we conducted a case-control study to investigate the relationship between polymorphisms of genes responsible for estrogen biosynthesis (CYP17, cytochrome P450c17a and CYP19, aromatase cytochrome P450) and estrogen sulfation of inactivation (SULT1A1, sulfotransferaselA1) and the risk of breast cancer in Chinese women. Methods This study involved 213 breast cancer patients and 430 matched controls. PCR-based restriction fragment length polymorphism (RFLP) and short tandem repeat polymorphism (STRP) assays were used to detect the mononucleotide transition of CYP17 and SULT1A1 and tandem repeat polymorphism of CYP19. Logistic regression analyses were used to determine OR and 95% Cl of each and all three high-risk genotypes, of all three genotypes combined, and of estrogen exposure factors. The relationship between each high-risk genotype and clinical pathological characteristics were also assessed. Results The frequency of A(2) allele of CYP17 was 49.8% in cases and 49.1% in controls (P = 0.82). The frequency of His allele of SULT1A1 was significantly higher in cases (13.6%) than in controls (9.5%) (P < 0.05). There was also significant difference of the (TTTA)(10) allele of CYP19 which was 12.4% in cases and 8.2% in controls (P < 0.05). When the CYP17 A(2) allele, CYP19 (TTTA)(10) and SULT1A1 His allele were considered as the "putative high-risk" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P = 0.05). In multivariate analysis, the SULT1A1 genotype remained the most significant determinant for breast cancer, with OR = 2.37 (95% CI 1.23-4.74), followed by CYP19, with OR = 1.75 (95% CI 1.27-3.56). The (TTTA)(10) allele of CYP19 was associated with tumor size, and the His allele of SULT1A1 associated with status of lymph node metastasis. Conclusions This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.
引用
收藏
页码:1507 / 1516
页数:10
相关论文
共 50 条
  • [41] Estrogen-metabolizing gene polymorphisms, but not estrogen receptor-α gene polymorphisms, are associated with the onset of menarche in healthy postmenopausal Japanese women
    Gorai, I
    Tanaka, K
    Inada, M
    Morinaga, H
    Uchiyama, Y
    Kikuchi, R
    Chaki, O
    Hirahara, F
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02): : 799 - 803
  • [42] Evaluation of Breast Cancer Risk in a Multigenic Model Including Low Penetrance Genes Involved in Xenobiotic and Estrogen Metabolisms
    Delort, Laetitia
    Satih, Samir
    Kwiatkowski, Fabrice
    Bignon, Yves-Jean
    Bernard-Gallon, Dominique J.
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2010, 62 (02): : 243 - 251
  • [43] Association of polymorphisms in one-carbon metabolizing genes with breast cancer risk in Syrian women
    Lajin, Bassam
    Sakur, Amir Alhaj
    Ghabreau, Lina
    Alachkar, Amal
    TUMOR BIOLOGY, 2012, 33 (04) : 1133 - 1139
  • [44] Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years
    Honma, N
    Takubo, K
    Sawabe, M
    Arai, T
    Akiyama, F
    Sakamoto, G
    Utsumi, T
    Yoshimura, N
    Harada, N
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (02): : 607 - 613
  • [45] Genetic variation in the major mitotic checkpoint genes and risk of breast cancer: a multigenic study on cancer susceptibility
    Wang, Ping
    Wang, Yong
    Yan, Haichao
    Xie, Qiuping
    Zhao, Liang
    Xu, Shaoming
    Zhao, Qunzi
    TUMOR BIOLOGY, 2014, 35 (07) : 6701 - 6705
  • [46] Estrogen-metabolizing gene polymorphisms but not estrogen receptor gene polymorphisms are associated with the onset of menarche and years of menstruation in healthy postmenopausal Japanese women.
    Gorai, I
    Tanaka, K
    Inada, M
    Morinaga, H
    Uchiyama, Y
    Kikuchi, R
    Chaki, O
    Hirahara, F
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S189 - S189
  • [47] Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes: a multigenic study on cancer susceptibility
    Lo, Yen-Li
    Yu, Jyh-Cherng
    Chen, Shou-Tung
    Hsu, Giu-Cheng
    Mau, Yi-Chien
    Yang, Show-Lin
    Wu, Pei-Ei
    Shen, Chen-Yang
    CARCINOGENESIS, 2007, 28 (05) : 1079 - 1086
  • [48] Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia
    Gulyaeva, Lyudmila F.
    Mikhailova, Olga N.
    PustyInyak, Vladimir O.
    Kim, Inessa V.
    Gerasimov, Alexei V.
    Krasilnikov, Sergey E.
    Filipenko, Maxim L.
    Pechkovsky, Eugene V.
    HORMONAL CARCINOGENESIS V, 2008, 617 : 359 - 366
  • [49] Association of rs4646903 and rs1048943 CYP1A1 estrogen-metabolizing gene polymorphisms with estrogen receptor-positive breast cancer in Kenyan women
    Murithi, Mary
    Nyanjom, Steven
    Mobegi, Victor
    Shahin, Sayed
    Makokha, Francis
    ARCHIVES OF BIOLOGICAL SCIENCES, 2023, 75 (01) : 57 - 67
  • [50] RISK OF BLADDER CANCER IN RELATION TO POLYMORPHISMS OF XENOBIOTIC METABOLIZING ENZYME GENES
    Sasaki, Takamitsu
    Horikawa, Miho
    Hiratsuka, Masahiro
    Orikasa, Kazuhiko
    Sato, Makoto
    Arai, Yoichi
    Ishikawa, Masaaki
    Mizugaki, Michinao
    DRUG METABOLISM REVIEWS, 2007, 39 : 110 - 110